Ignite Creation Date:
2025-12-24 @ 2:35 PM
Ignite Modification Date:
2026-02-03 @ 9:34 PM
Study NCT ID:
NCT04337359
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2021-01-26
First Post:
2020-04-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness
Sponsor:
Novartis Pharmaceuticals
Organization: